Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation.
Clicks: 26
ID: 280525
2023
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
0.6
/100
2 views
2 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Tweetable abstract Present evidence supports the use of intensified pharmacologic monitoring of #imatinib including #TherapeuticDrugMonitoring and #PGx to improve outcomes in patients with GI stromal tumor. Future studies need to address emerging questions to facilitate implementation in clinics.
| Reference Key |
gagno2023therapeuticpharmacogenomics
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Gagno, Sara;Fratte, Chiara Dalle;Posocco, Bianca;Buonadonna, Angela;Fumagalli, Arianna;Guardascione, Michela;Toffoli, Giuseppe;Cecchin, Erika; |
| Journal | Pharmacogenomics |
| Year | 2023 |
| DOI | 10.2217/pgs-2023-0198 |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.